文献速递瓣膜外科

AUTHEARTVISIT研究:经导管与外科主动脉瓣置换术的中期生存比较

Selection for transcatheter versus surgical aortic valve replacement and mid-term survival: results of the AUTHEARTVISIT study.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

基于奥地利2010至2020年保险基金数据的回顾性全国队列研究,纳入18882例严重主动脉瓣狭窄患者,比较经导管主动脉瓣置换术(TAVR)与外科生物瓣主动脉瓣置换术(sB-AVR)的长期死亡与并发症。中位随访5.8年,TAVR组全因死亡风险显著高于sB-AVR组(HR 1.552,95%CI 1.469-1.640,P<0.001),倾向评分匹配后HR 1.510(1.403-1.625,P<0.001)。

要点

  • TAVR组全因死亡风险显著高于sB-AVR组,HR 1.552(95%CI 1.469-1.640,P<0.001)。
  • 倾向评分匹配后TAVR组死亡风险仍较高,HR 1.510(95%CI 1.403-1.625,P<0.001)。
  • sB-AVR组估计中位生存8.8年,TAVR组为5年;5年生存概率sB-AVR组0.664 vs TAVR组0.409。

核心结论

  • 在≥65岁严重症状性主动脉瓣狭窄患者中,选择TAVR与sB-AVR相比,在超过2年随访中全因死亡风险显著更高。

研究设计与样本

  • 回顾性全国人口队列研究,分析奥地利保险基金2010年至2020年个体数据。
  • 共纳入18882例因严重主动脉瓣狭窄行主动脉瓣置换术患者,其中sB-AVR组11749例(62.2%),TAVR组7133例(37.8%)。
  • 中位随访5.8年(95%CI 5.7-5.9),最长12.3年;主要结局为全因死亡,在总体和倾向评分匹配人群中评估。

主要发现

  • 总体人群TAVR组全因死亡风险高于sB-AVR组,HR 1.552(95%CI 1.469-1.640,P<0.001)。
  • 倾向评分匹配后TAVR组全因死亡风险仍高于sB-AVR组,HR 1.510(95%CI 1.403-1.625,P<0.001)。
  • sB-AVR组估计中位生存8.8年(95%CI 8.6-9.1),TAVR组5年(95%CI 4.9-5.2)。
  • 总体5年生存概率sB-AVR组0.664(95%CI 0.664-0.686) vs TAVR组0.409(95%CI 0.378-0.444);倾向评分匹配后分别为0.690(0.674-0.707)和0.560(0.540-0.582)。
  • 65-75岁和>75岁亚组分析均显示选择sB-AVR的患者生存获益显著;其他死亡预测因素包括年龄、性别、既往心力衰竭、糖尿病和慢性肾脏病。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Limited data are available from randomized trials comparing outcomes between transcatheter aortic valve replacement (TAVR) and surgery in patients with different risks and with follow-up of at least 4 years or longer. In this large, population-based cohort study, long-term mortality and morbidity were investigated in patients undergoing aortic valve replacement (AVR) for severe aortic stenosis using a surgically implanted bioprosthesis (surgical/biological aortic valve replacement; sB-AVR) or TAVR. METHODS: Individual data from the Austrian Insurance Funds from 2010 through 2020 were analysed. The primary outcome was all-cause mortality, assessed in the overall and propensity score-matched populations. Secondary outcomes included reoperation and cardiovascular events. RESULTS: From January 2010 through December 2020, a total of 18 882 patients underwent sB-AVR (n = 11 749; 62.2%) or TAVR (n = 7133; 37.8%); median follow-up was 5.8 (95% CI 5.7-5.9) years (maximum 12.3 years). The risk of all-cause mortality was higher with TAVR compared with sB-AVR: hazard ratio 1.552, 95% confidence interval (CI) 1.469-1.640, P < 0.001; propensity score-matched hazard ratio 1.510, 1.403-1.625, P < 0.001. Estimated median survival was 8.8 years (95% CI 8.6-9.1) with sB-AVR versus 5 years (4.9-5.2) with TAVR. Estimated 5-year survival probability was 0.664 (0.664-0.686) with sB-AVR versus 0.409 (0.378-0.444) with TAVR overall, and 0.690 (0.674-0.707) and 0.560 (0.540-0.582), respectively, with propensity score matching. Separate subgroup analyses for patients aged 65-75 years and >75 years indicated a significant survival benefit in patients selected for sB-AVR in both groups. Other predictors of mortality were age, sex, previous heart failure, diabetes and chronic kidney disease. CONCLUSIONS: In this retrospective national population-based study, selection for TAVR was significantly associated with higher all-cause mortality compared with sB-AVR in patients ≥65 years with severe, symptomatic aortic stenosis in the >2-year follow-up.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Auer J, Krotka P, Reichardt B, et al. Selection for transcatheter versus surgical aortic valve replacement and mid-term survival: results of the AUTHEARTVISIT study. Eur J Cardiothorac Surg. 2024. PMID: 38867365. doi:10.1093/ejcts/ezae214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。